Receptor specific atrial natriuretic peptides
    8.
    发明授权
    Receptor specific atrial natriuretic peptides 有权
    受体特异性心房利钠肽

    公开(公告)号:US06525022B1

    公开(公告)日:2003-02-25

    申请号:US09154390

    申请日:1998-09-16

    IPC分类号: A61K3812

    CPC分类号: C07K14/58 A61K38/00

    摘要: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

    摘要翻译: 含有各种取代,特别是G16R的人受体选择性心房利钠因子变体对人A受体显示相同的效力和结合亲和力,但对人清除或C-受体的亲和力降低。 这些ANF变体具有利钠,利尿和血管舒张活性,但具有增加的代谢稳定性,使其适合于治疗充血性心力衰竭,急性肾衰竭和肾性高血压。

    Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
    10.
    发明申请
    Imidazo[4,5-d]pyrimidines, their uses and methods of preparation 有权
    咪唑并[4,5-d]嘧啶,其用途和制备方法

    公开(公告)号:US20060052602A1

    公开(公告)日:2006-03-09

    申请号:US11190751

    申请日:2005-07-26

    IPC分类号: C07D473/02

    摘要: The present invention relates to pharmaceutical compositions for the treatment or prevention of viral infections comprising as an active principle at least one imidazo[4,5-c]pyrimidine having the general formula (A): wherein the substituents are described in the specification. The invention also relates to processes for the preparation of compounds according to the invention having above mentioned general formula, their pharmaceutically acceptable formulations and their use as a medicine or to treat or prevent viral infections.

    摘要翻译: 本发明涉及用于治疗或预防病毒感染的药物组合物,其包含作为活性成分的至少一种具有通式(A)的咪唑并[4,5-c]嘧啶: